Comparison
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 vs 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Exogenous Maternal Derived Androgen and 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
A condition caused when a pregnant person takes hormone medications containing androgens, affecting fetal development. The fetus has XX chromosomes. Stopping the offending agent is key, with specialist care for affected infants.
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
A rare condition affecting how certain hormones are processed in the body, which can influence sexual development. Treatment may involve hormone therapy and specialist care.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
Variable
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
0-16
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
severe
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
Chronic
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
No
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
reproductive
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
endocrine
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
endocrine
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
endocrine
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-exogenous-maternal-derived-androgen-C5679874 and 3-oxo-5-alpha-steroid-delta-4-dehydrogenase-deficiency-C0268297 differ in severity
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 | 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 | Discriminating power |
|---|---|---|---|
| Genital development | An XX fetus may show androgen-related atypical genital development. | Sexual development may be altered, but the exact pattern is not established here. | Moderate |
| Exposure history | Linked to androgen-containing medication taken during pregnancy. | No maternal medication exposure is required by the source description. | High |
| Chromosomal context | The source specifies XX chromosomes. | Karyotype is not stated and requires confirmation. | High |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 when
Documented pregnancy exposure to androgen medication and an XX infant
This matches the stated exogenous cause.
High
Atypical genital findings without confirmed intrinsic enzyme disease
Exposure history is the main supplied discriminator.
Moderate
Ongoing exposure can still be stopped
The source identifies stopping the offending agent as key.
High
Choose 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 when
Altered sexual development without identified exogenous androgen
The source frames an intrinsic hormone-processing problem.
Moderate
Specialist concern for disordered androgen metabolism
The concept name suggests enzyme deficiency, but confirmation is required.
Moderate
Hormone therapy is being considered
The source says treatment may include hormone therapy and specialist care.
Low
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 | 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 | Interpretation |
|---|---|---|---|
| Karyotype | XX is specified by the concept. | Not established in the supplied data. | Do not infer karyotype for the right condition without testing. |
| Medication and exposure review | Androgen-containing maternal medication is central. | No such exposure is required. | A positive history supports the left explanation but does not exclude other conditions. |
| Hormone studies | May reflect timing and type of exogenous exposure; no cutoff is supplied. | May suggest altered hormone processing; exact pattern is not established. | Results require specialist interpretation and are not diagnostic alone. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
- Outcome
- Described as severe and chronic, but individual outcome is not established.
- Factors
- Exposure timing, whether exposure stops, and infant findings may matter.
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
- Outcome
- Described as moderate and chronic, without a quantified outcome.
- Factors
- Hormone-processing severity and response to specialist care may matter.
Time frame: Onset is variable on the left and listed as 0–16 on the right.
No prevalence, mortality, or definitive prognosis is supplied.
Complications comparison
| Complication | Presentation |
|---|---|
| Atypical genital development | May follow prenatal androgen exposure. May occur through disordered hormone processing. Appearance alone does not establish either cause. |
| Need for specialist care | Infant assessment and removal of ongoing exposure are emphasized. Endocrine follow-up and possible hormone therapy may be needed. Specific interventions and doses are not established here. |
| Psychosocial burden | Families may face uncertainty about cause and development. A chronic rare condition may require repeated counseling. Impact varies and should not be assumed from severity labels alone. |
Patient education highlights
- HighCause
The left condition is linked to maternal androgen medication; the right concerns internal hormone processing.
- HighTesting
An abnormal finding or appearance is not itself a final diagnosis and needs clinician review.
- MediumCare
Both may need specialist follow-up; medication changes or hormone therapy require individualized advice.